Radiotherapy-induced glioblastoma: distinct differences in overall survival, tumor location, pMGMT methylation and primary tumor epidemiology in Hong Kong chinese patients

被引:5
|
作者
Woo, Peter Y. M. [1 ]
Lee, Jennifer W. Y. [1 ]
Lam, Sandy W. [1 ]
Pu, Jenny K. S. [2 ]
Chan, Danny T. M. [3 ]
Mak, Calvin H. K. [4 ]
Ho, Jason M. K. [5 ]
Wong, Sui-To [5 ]
Po, Yin-Chung [6 ]
Lee, Michael W. Y. [7 ]
Chan, Kwong-Yau [1 ]
Poon, Wai-Sang [3 ]
机构
[1] Kwong Wah Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[2] Queen Mary Hosp, Dept Surg, Div Neurosurg, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Dept Surg, Div Neurosurg, Shatin, Hong Kong, Peoples R China
[4] Queen Elizabeth Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[5] Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[6] Princess Margaret Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[7] Pamela Youde Nethersole Eastern Hosp, Dept Neurosurg, Hong Kong, Peoples R China
关键词
Glioblastoma; radiotherapy-induced; radiation-induced; methyguanine methyltranferase;
D O I
10.1080/02688697.2021.1881445
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Radiotherapy-induced glioblastomas (RIGB) are a well-known late and rare complication of brain irradiation. Yet the clinical, radiological and molecular characteristics of these tumors are not well characterized. Methods This was a retrospective multicentre study that analysed adult patients with newly diagnosed glioblastoma over a 10-year period. Patients with RIGB were identified according to Cahan's criteria for radiation-induced tumors. A case-control analysis was performed to compare known prognostic factors for overall survival (OS) with an independent cohort of IDH-1 wildtype de novo glioblastomas treated with standard temozolomide chemoradiotherapy. Survival analysis was performed by Cox proportional hazards regression. Results A total of 590 adult patients were diagnosed with glioblastoma. 19 patients (3%) had RIGB. The mean age of patients upon diagnosis was 48 years +/- 15. The mean latency duration from radiotherapy to RIGB was 14 years +/- 8. The mean total dose was 58Gy +/- 10. One-third of patients (37%, 7/19) had nasopharyngeal cancer and a fifth (21%, 4/19) had primary intracranial germinoma. Compared to a cohort of 146 de novo glioblastoma patients, RIGB patients had a shorter median OS of 4.8 months versus 19.2 months (p-value: <.001). Over a third of RIGBs involved the cerebellum (37%, 7/19) and was higher than the control group (4%, 6/146; p-value: <.001). A fifth of RIGBs (21%, 3/19) were pMGMT methylated which was significantly fewer than the control group (49%, 71/146; p-value: .01). For RIGB patients (32%, 6/19) treated with re-irradiation, the one-year survival rate was 67% and only 8% for those without such treatment (p-value: .007). Conclusion The propensity for RIGBs to develop in the cerebellum and to be pMGMT unmethylated may contribute to their poorer prognosis. When possible re-irradiation may offer a survival benefit. Nasopharyngeal cancer and germinomas accounted for the majority of original malignancies reflecting their prevalence among Southern Chinese.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 15 条
  • [11] TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS
    Ellingson, Benjamin
    Abrey, Lauren
    Nelson, Sarah
    Garcia, Josep
    Chinot, Olivier
    Saran, Frank
    Nishikawa, Ryo
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Butowski, Nicholas
    Ligon, Keith
    Gerstner, Elizabeth
    Colman, Howard
    Taylor, Jennie
    Arrillaga-Romany, Isabel
    Huang, Ray
    Pope, Whitney
    Reardon, David
    Batchelor, Tracy
    Wen, Patrick Y.
    Prados, Michael
    Cloughesy, Timothy F.
    NEURO-ONCOLOGY, 2017, 19 : 161 - 161
  • [12] Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
    Venook, Alan P.
    Niedzwiecki, Donna
    Innocenti, Federico
    Fruth, Briant
    Greene, Claire
    O'Neil, Bert H.
    Shaw, James Edward
    Atkins, James Norman
    Horvath, Laura E.
    Polite, Blase N.
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen Mary
    Goldberg, Richard M.
    Hochster, Howard S.
    Blanke, Charles David
    Schilsky, Richard L.
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [13] Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance).
    Venook, Alan P.
    Ou, Fang-Shu
    Lenz, Heinz -Josef
    Kabbarah, Omar
    Qu, Xueping
    Niedzwiecki, Donna
    Zemla, Tyler
    Goldberg, Richard M.
    Hochster, Howard S.
    O'Neil, Bert H.
    Sanoff, Hanna Kelly
    Mayer, Robert J.
    Bertagnolli, Monica M.
    Blanke, Charles David
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [14] Association of primary, nodal and total metabolic tumor volume with response assessment and overall survival in non-surgical non-small-cell lung cancer (NSCLC) patients treated by radical chemo-radiotherapy
    Iravani, Amir
    Turgeon, Guy-Anne
    Akhurst, T.
    Bressel, Mathias
    Everitt, Sarah
    Siva, Shankar
    Hofman, Michael
    Hicks, Rodney
    Ball, David
    MacManus, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [15] Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
    Kasper, S.
    Cheng, A.
    Rouyer, M.
    Foch, C.
    Lamy, F.
    Esser, R.
    Batech, M.
    Wong, C.
    Zhang, A.
    Brodowicz, T.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S114 - S114